細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Cyclin D1 (CCND1) ,etc. by FLIA (Flow Luminescence Immunoassay)
CCN-D1; BCL1; PRAD1; U21B31; G1/S-Specific Cyclin-D1; Parathyroid Adenomatosis 1; B-Cell CLL/Lymphoma 1; G1/S-Specific Cyclin D1; PRAD1 oncogene
（注：單次混測多因子不超過8個指標 ）
- 編號LMA585Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.01-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.003 ng/mL.
- 樣本類型tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 2702 ¥ 2806 ¥ 2962 ¥ 3170 ¥ 3377 ¥ 3689 ¥ 4157 ¥ 5196 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 90-105 | 97 |
| EDTA plasma(n=5) | 99-105 | 102 |
| heparin plasma(n=5) | 98-105 | 102 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-101% | 89-103% | 94-105% | 96-104% |
| EDTA plasma(n=5) | 80-98% | 78-91% | 84-97% | 91-101% |
| heparin plasma(n=5) | 94-101% | 80-92% | 81-94% | 94-101% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA585Ra01 | 細胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA585Ra01 | 細胞周期素D1(CCND1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA585Ra71 | 細胞周期素D1(CCND1)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA585Ra81 | 細胞周期素D1(CCND1)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| SEA585Ra | 細胞周期素D1(CCND1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA585Ra | 細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA585Ra01 | 細胞周期素D1(CCND1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| Biochemical Pharmacology | Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells [ScienceDirect: S0006295211002097] |
| Leukemia & Lymphoma | The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-62 human leukemia cells [Pubmed: 24138332] |
| The Journal of Clinical Endocrinology and Metabolism | Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. [Pubmed: 23969186] |
| Nutrition and Cancer | Common Food Additive Carrageenan Stimulates Wnt/ β-Catenin Signaling in Colonic Epithelium by Inhibition of Nucleoredoxin Reduction [Pubmed:24328990] |
| The International Journal of Biochemistry &?Cell?Biology | MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human … [pubmed:27783537] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
| Investigational new drugs | Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. [pubmed:29273857] |
| Biochemical Pharmacology | Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase?… [Pubmed:29660315] |
| Apoptosis | Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells [Pubmed:29468481] |
| Oncology?Reports | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo [Pubmed:29517106] |
| Oncology Reports | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [Pubmed:29517103] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
| Middle East Journal of Rehabilitation and Health | Antiapoptotic Effects of Continuous Training and Selenium Consumption on the Liver Tissue of Cadmium-Exposed Rats [Pubmed: 10.5812/mejrh.91278] |
| European journal of medicinal chemistry | Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity [Pubmed: 31216504] |
